chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Sensitive front teeth; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP).  A 70 year-old female patient received bnt162b2 (BNT162B2), administered in arm (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. Relevant medical history included: "Arthritis" (unspecified if ongoing); "Sometimes gets weak" (unspecified if ongoing); "Back problem" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: HYPERAESTHESIA TEETH (non-serious), outcome "unknown", described as "Sensitive front teeth". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Stated that her first dose was on 04-Mar-2021 and second dose was on 16-Apr-2021; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Stated that her first dose was on 04-Mar-2021 and second dose was on 16-Apr-2021) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Allergies (medications, food and other products) was reported as no. The patient never had COVID positive test or diagnosis. The patient not had Medical history relating to mentioned adverse event and both acute and chronic illnesses at the time of vaccination.  Concurrent medical conditions included Allergic reaction to drug (Codeine, but does not have an allergy to Codeine).   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Stated that her first dose was on 04-Mar-2021 and second dose was on 16-Apr-2021). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Stated that her first dose was on 04-Mar-2021 and second dose was on 16-Apr-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   It was reported that the patient had no health conditions and took no medication. Other vaccines given within 1 month prior to Moderna COVID-19 vaccine was reported as no. It was reported that the patient had no reaction to any other of the shots.  No treatment information was reported.   This case was linked to MOD-2022-545322 (Patient Link).
said that he was recommended by "both cardiologists" he consulted, to not get the second dose; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program.  A 55 year-old male patient received bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CARDIAC DISORDER (non-serious), outcome "unknown", described as "said that he was recommended by "both cardiologists" he consulted, to not get the second dose".  The lot number for the vaccine, [BNT162B2] was not provided and will be requested during follow-up.  Follow-up (02Mar2022): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.
The 1st thing I noticed was I had an overall sense of malaise. I then had a rash that started at my neck and then it went all the way down to my ankles. The rash was slightly elevated. The next day I woke up in the night with bad pain in my back. It felt like my heart was being squeezed, and it felt like something was going through it. It then passed. These symptoms went on for awhile. I had a pain in my leg. I woke up in the morning and my leg would just hurt. The muscles around my ankles would hurt too. Then that went away. I would get a tingling feeling in my body that would happen with my arms, legs, and hands. I had a hard time getting up in the morning. When I would get up from my bed and then walk to my kitchen, I would break out in  a sweat. I haven't felt right for weeks. My heart feels like it could jump out of my chest. I never had any respiratory symptoms. I had some odd pain. My arm would really hurt and then it would just go away. A lot of my hair fell out. I felt very tired. In the morning my hands, arms, and elbows felt weak. Then it would go away after I got up. I also had some night sweats. One day I could barely pick up my leaf blower. I  was also riding a bicycle one day and I felt fatigue in my legs. All of these symptoms lasted up until the end of January 2022.
Heart rate went up to 120-130 while sitting down.  I got dizzy.  I went to  and was sent to the Emergency .  They did an EKG and some blood work.  After about an hour my heart rate went back down and I was fine.
After the booster, my tongue felt "different/there is a loss of feeling in part of my tongue and it has very slightly effected my speech; After the booster, my tongue felt "different/there is a loss of feeling in part of my tongue and it has very slightly effected my speech; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 16Oct2021 (Lot number: EW0191) at the age of 47 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Known allergies: acai berry sensitivity" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EN6198), administration date: 05Mar2021, when the patient was 46 years old, for Covid-19 Immunization, reaction(s): "change in smell and taste", "change in smell and taste"; Bnt162b2 (Dose Number: 2, Batch/Lot No: EP6955, Location of injection: Arm Left), administration date: 26Mar2021, when the patient was 46 years old, for Covid-19 Immunization. The following information was reported: PARAESTHESIA ORAL (non-serious), SPEECH DISORDER (non-serious), outcome "not recovered" and all described as "After the booster, my tongue felt "different/there is a loss of feeling in part of my tongue and it has very slightly effected my speech". The event "after the booster, my tongue felt "different/there is a loss of feeling in part of my tongue and it has very slightly effected my speech" and "after the booster, my tongue felt "different/there is a loss of feeling in part of my tongue and it has very slightly effected my speech" was evaluated at the physician office visit. Therapeutic measures were not taken as a result of paraesthesia oral, speech disorder.  Additional information: About 15 minutes after the first of the three shots, she experienced a change in smell and taste. She had hoped it would go away but it has remained almost the entire year. After the booster, her tongue felt different. She realized lately that there was a loss of feeling in part of my tongue and it has very slightly effected my speech. It was tip of my tongue. The rest of her mouth was also slightly effected but she was not able to compensate by over enunciating. Patient not experienced Covid 19 before administration of vaccine and not tested positive for covid after vaccination.  No follow-up attempts are possible. No further information is expected.
Pt recvd 3 doses of Engerix-B & it was determined that pt was a non-responser; Booster dose of Engerix-B given 13FEB91;
This spontaneous report was received from a nurse and refers to an 8 day old patient (gender unknown). No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On 13-MAR-2017, the patient was vaccinated with an expired dose of injectable RECOMBIVAX HB (Lot # K018180 and expiration date 17-SEP-2016) for prophylaxis (dose, frequency, route of administration and anatomical location were not reported) (product use issue). There were no adverse effects reported. Additional information has been requested.
Temperature of 100.9. Began 36 hours after shot.  Lasted for 24 hours. Very sore and swollen lymph nodes in left armpit.
Below injection-sore, lumpy, raised skin about the size of a golf ball or a little bigger but not raised that high.
Patient was hospitalized due to breakthrough infection. Patient received Pfizer vaccine (2nd dose in series) on 03/13/2021. Patient was hospitalized from 12/28/2021 - 12/30/2021. Below is copied from discharge summary:   The patient is a 83 y.o. male patient who is being discharged today.   Hospital Course:    AKI on CKD  Likely 2/2 decreased fluid intake Creatinine  1.1 at baseline  Received IVF  Renally dose medications  Avoid nephrotoxic agents    Failure to thrive  - tolerating PO diet well COVID-19  FTT likely 2/2 COVID-19  PT/OT: back to STR Pt not requiring oxygen  Supportive care with Tylenol for fevers, DuoNebs p.r.n., and dextromethorphan/guaifensin    Elevated troponin  Troponin elevation in the setting of COVID-19 ECG showing bifascicular block, seen on previous ECGs  No change in delta  No chest pain, likely due to AKI   Hypermagnesemia  Mild, monitor    Normocytic anemia  Stable, monitor    Paroxysmal atrial fibrillation  ECG showing bifascicular block  Rate controlled  Cont Eliquis    COPD No exacerbation  Duonebs prn     Hypertension  Resume losartan   Dementia At baseline  Cont Aricept and Memantine    Gastroesophageal reflux disease Home medication non formulary, cont with Protonix    Patient is discharged in stable condition with stable vital signs. All questions rearding hospital course and plan of care after discharge have been answered to satisfaction. Prescriptions for medications needed to be taken after discharge have been given to patient. Patient has been instructed to follow up with PCP, MD within the next 7 days after discharge. Patient verbalizes understanding all given instructions and has no further doubts regarding discharge.
The symptoms began about 1 to 2 weeks after the H1N1 vaccine was given on November 24, 2009, which ultimately lead to my miscarriage. During my first prenatal doctors appointment, on Dec. 7th, I should have been 6 weeks along. When the doctor did an ultrasound they said they couldnt see an embryo and that I was probably only 4.5 weeks along, which did not add up. About 2 week later, on December 22, I began heavy bleeding. On December 23, I had another ultrasound which confirmed the pregnancy was no longer viable.  I am in a mom's group and over the past month 4 of us found out we were pregnant and all of us miscarried, and all us of received the H1N1 vaccine. This is more than a coincidence.  12/31/09:  Prenatal records received for dates of service 12/11/09 to 12/23/09.  Dx:  Failed intrauterine pregnancy.    Gravida 1, Para 0, LMP:  10/31/09.  Transvaginal US shows failed intrauterine pregnancy with hemorrhagic byproducts identified within the endometrial cavity.
During the night the day after receiving the shot I had severe chills accompanied by diarrhea and stomach pain.  The next morning I also began experiencing nausea accompanied by stomach growling.  For the next 5 days or so I experienced all of the above.  On day 6  the diarrhea was replaced by constipation.  By day 9 or so the diarrhea and constipation ended but all of the other symptom--nausea, mild stomach pain and stomach growling persisted.  During week number four I went to my above health care provider and also reported my vaccination reactions to the pharmacy where I received the shot (Publix).
Delayed reaction; vaccination site cellulitis; Induration at injection site; Redness at injection site; This spontaneous case was reported by a physician and describes the occurrence of SKIN REACTION (Delayed reaction), VACCINATION SITE CELLULITIS (vaccination site cellulitis), VACCINATION SITE INDURATION (Induration at injection site) and VACCINATION SITE ERYTHEMA (Redness at injection site) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039k20A) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SKIN REACTION (Delayed reaction), VACCINATION SITE CELLULITIS (vaccination site cellulitis), VACCINATION SITE INDURATION (Induration at injection site) and VACCINATION SITE ERYTHEMA (Redness at injection site). At the time of the report, SKIN REACTION (Delayed reaction), VACCINATION SITE CELLULITIS (vaccination site cellulitis), VACCINATION SITE INDURATION (Induration at injection site) and VACCINATION SITE ERYTHEMA (Redness at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Reporter did not allow further contact
2 days after receiving the vaccine started having a headache and odd visual changes - lights in sparkly patterns, seeing something move in periphery of vision that wasn't there.  No fever, no aches, arm didn't hurt, no nausea, was able to continue working so no change in mental status.  Lasted until 1/23/2021 and stopped completely. Is asymptomatic now.
Persistent soreness in arm. Patient has used a heating pad, but has not felt any relief.
Information has been received from a consumer and a registered nurse concerning a 4 year old female child with eczema at the time of vaccination, a penicillin allergy, an allergy to amoxicillin, a seizure disorder, a developmental delay and a history of HEADDS and pneumococcal meningitis at 4 months of age. The registered nurse reported that on 2/23/00 the child was vaccinated SC in the left thigh with a first dose of MMR (second generation) (lot # not reported) and on 12/12/02 the child was vaccinated SC in the left thigh with a second dose of MMR (second generation) (lot # 642702/0350). The patient's mother reported that the first dose of MMR (second generation) was in December 1999 and the second dose was on 12/19/02. Concomitant therapy included levetiracetam, oxcarbazepine, and clorazepate dipotassium. The consumer reported that her daughter experienced an unusual increase in the number of seizures that she was having immediately after being vaccinated with the first and second doses of MMR (second generation). The registered nurse reported that the patient experienced increased seizure activity after receiving MMR. NOticed after first MMR, then resolved. Unspecified medical attention was sought. On 12/19/02 the child had a PA and Lateral chest x-ray done for cough, seizure, which revealed that the chest was normal. The child had an electroencephalogram done on 2/25/03, which revealed no rhythms that would normally be seen in a child of this age. There was no occipital dominant rhythm. The tracing was actually quite similar to one performed on 10/30/02, after the child had received lorazepam. It was reported that while the child was awake, there was a mixed frequency background of theta and delta rhythms centrally. Very low-voltage fast activity was seen. There was 1 recorded seizure which began at a lower voltage 5 to 5 Hz spike wave in the left hemisphere, and then gradually generalized. Clinically, right arm flexion and eye movement were noted. The background showed a progression of high-voltage slow spike wave pattern, which was generalized, but of much higher voltage on the left as compared to the right. Th tracings, otherwise, showed frequent multifocal spikes occurring in the left hemisphere. As was previously noted, they were frequent at C3, but also seen at F3, F7, and T5. During brief sleep, a few scattered vertex waves were noted, but no sleep spindles were seen. The overall impression was reported as: nearly constant left hemisphere multifocal spikes; one brief electroencephalographic seizure reported (approximately 90 seconds total); disorganized backgroud both awake and asleep and it was noted overall the tracings was quite similar to what was seen previously. The outcome for these events is unknown. Upon internal review, the increase in the number of seizures was determined to be an other important medical event (OMIC). No further information is expected.
On or about 09/01/2015 my spouse, 82 and I, 91 went to pharmacy and received the senior flu immunization. On the second day after, at exactly at the same time we both began to feel slightly ill at east which quickly became worse over the next several days to dizziness, weakness and other hard to describe symptoms that really have not fully left completely to this day, some 3 months later. This 4x vaccine should not be given to seniors of advanced age without prior warning.
Woke up in the middle of the night with body aches, shivering. Fever of 101 (fever has continued to persist ranging from 100-101 whilst taking acetaminophen), Vomiting/nausea, Significant tenderness at injection site, Fluctuating between feeling very hot and very cold.
Pt was vaccinated on 1/21/21.  Presented to ED on 1/23/21 after stroke like symptoms that started at 7:30am.  Symptoms resolved over the morning, admitted to hospital for observation, MRI confirmed small infarct R central gyrus, consistent with symptoms.  Started on plavix, continued on aspirin.
Minimum of two absence seizures three days after the vaccinations in morning/early afternoon followed by a tonic-clonic seizure in the afternoon at home and two more in the ER.  Lips turned blue in ER.  Initial Ativan dose in ER did not stop seizures, so they gave her Keppra as well.  She was admitted and had several more  seizures, roughly every 75 minutes according to when her O2 stats dropped while she was sedated.   The seizures lasted less than 30 seconds initially and were over 2 minutes later.  After a day or so on two medications,  she was  irritable, twitchy, and clawing/climbing all over me and wasn't sleeping well, so they took her off one medication and was left on Keppra.  After being discharged and adjusting her dosage she remained  seizure free on Keppra  2x/day for over two years until we tapered her off in the fall of 2017.   She has been seizure free since late January 2015 on meds and since the fall 2017 off the meds.  Whether related or not, she had a delay in walking (did not walk full time until almost 2 years old, has a speech delay, Selective Mutism, and suspected sensory issues (gait, sounds, textures).
fever; This is a spontaneous report from a program. A contactable female consumer reported for herself. A female patient of an unspecified age received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, solution for injection), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. It was reported that there was a call from a caller who has already received her first dose of the vaccine and wanted to be scheduled for second dose. Caller stated that she is also experiencing fever and wanted to know if she will go through that with the second dose. The outcome of the event was unknown.  No follow-up attempts are needed. information about lot/batch number cannot be obtained.
HSP diagnosis. Unable to walk or straighten out right leg, severe rash all over body, fever, stomach pains, swollen wrists.
Nose filled up I sneezed; felt a little bit itchy; This is a spontaneous report from a contactable consumer. A 72-year-old female patient received bnt162b2 (Pfizer-BioNTech covid-19 vaccine, Solution for injection), via an unspecified route of administration on 27Jan2021 at 01:45 as unknown, single for covid-19 immunisation. Medical history and concomitant medications were not reported. On an unspecified date, last night about 8 o'clock she had nose filled up and she sneezed and felt a little bit itchy, but no rash developed. The events assessed as non-serious. She took the Benadryl for the treatment and had no other health issues. The outcome of the events was recovered.  Follow-up attempts have been completed and no further information is expected.
eyes, welts, coughing, wheezing, Pulse Ox=90% RA- Angioedema-DTaP ordered-pt inadvertantly given Tdap
Patient was admitted to the hospital for Heart Failure and was discharged; Readmitted to the hospital for second time for heart related complications; Patient was scheduled to receive the second dose on 02Apr2021 but due to medical complications will not be able to receive the dose as scheduled; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of CARDIAC FAILURE (Patient was admitted to the hospital for Heart Failure and was discharged) and CARDIAC DISORDER (Readmitted to the hospital for second time for heart related complications) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse drug reaction (No reported medical history).    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CARDIAC FAILURE (Patient was admitted to the hospital for Heart Failure and was discharged) (seriousness criterion hospitalization), CARDIAC DISORDER (Readmitted to the hospital for second time for heart related complications) (seriousness criterion hospitalization) and PRODUCT DOSE OMISSION ISSUE (Patient was scheduled to receive the second dose on 02Apr2021 but due to medical complications will not be able to receive the dose as scheduled). At the time of the report, CARDIAC FAILURE (Patient was admitted to the hospital for Heart Failure and was discharged), CARDIAC DISORDER (Readmitted to the hospital for second time for heart related complications) and PRODUCT DOSE OMISSION ISSUE (Patient was scheduled to receive the second dose on 02Apr2021 but due to medical complications will not be able to receive the dose as scheduled) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was reported. Concomitant product use was not provided by the reporter.  Limited information regarding the events of cardiac failure and cardiac disorder has been provided at this time and a causal relationship cannot be excluded.  This report also refers to an event of dose omission.  There were no AEs specifically associated with this medication error; Sender's Comments: Limited information regarding the events of cardiac failure and cardiac disorder has been provided at this time and a causal relationship cannot be excluded.  This report also refers to an event of dose omission.  There were no AEs specifically associated with this medication error
Patient reports today, from 10/1/14 to 10/3/14 she felt achy, nauseous, and shaky and her legs were weak.
Ache pain from shoulder to but not including wrist for 3 days bad, subsided for a couple of days, and returned bad, continues intermittently especially when using are driving and reaching, has tried Tylenol without improvement, ibuprofen helps but after a couple of days the ibuprofen bothers stomach, heat helps temporarily, MD has suggested Neurontin or Lyrica to patient but she doesn't want to use them due to side effects in the past, patient mentioned acupuncture, I suggested check that with MD and perhaps physical therapy.
Erythema, pain and pruritus at the injection site lasting nine days. Treated with diphenhydramine and ibuprofen